Management of Pediatric Vaginal Candidiasis: Evidence‑Based Recommendations
Systemic Antifungal Therapy Dosing
- For children ≥ 2 years who require systemic treatment, a single oral dose of fluconazole 6 mg/kg is recommended as a loading dose (Praxis Medical Insights) 1.
- In infants and toddlers < 2 years, fluconazole 5 mg/kg/day has been used safely, although data are limited (Clinical Infectious Diseases) [2][3].
- Oral fluconazole exhibits > 93 % bioavailability, making oral and intravenous formulations essentially equivalent (Praxis Medical Insights) 1.
- Neonates display markedly prolonged fluconazole half‑life (55–90 h vs ≈ 30 h in adults), necessitating careful dosing adjustments (Clinical Infectious Diseases) 3.
- When fluconazole fails or resistance is documented, oral itraconazole solution 2.5 mg/kg twice daily (maximum 200 mg/day) for 14 days is an alternative (Praxis Medical Insights) 1.
Indications for Escalation to Systemic Therapy
- Systemic fluconazole should be considered after an adequate trial of topical therapy (7–14 days) has failed (Praxis Medical Insights) 1.
- Escalation is warranted if a severe infection with possible deep‑tissue involvement is suspected (Praxis Medical Insights) 1.
- Poor topical drug penetration due to anatomical factors also prompts systemic therapy (Praxis Medical Insights) 1.
- Clinical improvement is expected within 7 days of initiating oral fluconazole; lack of response should trigger fungal culture to assess for resistant species (Praxis Medical Insights) 1.
Alternative Systemic Options for Refractory or Invasive Disease
| Antifungal (Route) | Recommended Dose | Indication |
|---|---|---|
| Micafungin (IV) | 2–4 mg/kg/day | Severe or invasive disease (Clinical Microbiology & Infection; Praxis Medical Insights) [4][1][5] |
| Caspofungin (IV) | 70 mg/m² loading dose, then 50 mg/m²/day | Severe or invasive disease (Clinical Microbiology & Infection; Praxis Medical Insights) [4][1][5] |
| Liposomal amphotericin B (IV) | 3 mg/kg/day | Severe or invasive disease (Clinical Microbiology & Infection; Praxis Medical Insights) [4][1][5] |
Pre‑Escalation Considerations
- Verify that the patient (or caregiver) has applied the topical agent correctly (Praxis Medical Insights) 1.
- Ensure that hygiene measures and potential sources of reinfection have been addressed before moving to systemic therapy (Praxis Medical Insights) 1.
Species‑Specific Resistance
- Candida krusei is intrinsically resistant to fluconazole and should not be treated with this agent (Clinical Microbiology & Infection) 4.
- Candida glabrata often exhibits higher minimum inhibitory concentrations to fluconazole, reducing the reliability of this therapy (Clinical Microbiology & Infection) 4.
- If initial therapy fails, obtain a fungal culture to guide species‑directed treatment (Praxis Medical Insights) 1.
Special Populations
- In neonates and premature infants, amphotericin B deoxycholate 0.5–1 mg/kg/day is better studied than fluconazole for invasive candidiasis (Clinical Infectious Diseases) 6.
- Fluconazole dosing in this group is complicated by immature renal function and prolonged half‑life (Clinical Infectious Diseases) 3.
Monitoring and Follow‑up
- Ophthalmologic examination is required only for invasive or disseminated candidiasis, not for isolated vaginal infection (Praxis Medical Insights) 5.